Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Sagent Pharmaceuticals

Share:
Related SGNT
2 Biotech Stocks Deutsche Bank Just Initiated
5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Sagent Pharmaceuticals (NASDAQ: SGNT).

Morgan Stanley noted, “Total November IMS sales were $17MM establishing a 4Q12 run rate of $53MM in-line with MSe and Cns of $52MM and guidance of ~$50MM. However, the focus is now on 2013 commercial momentum and we are comfortable with our $227MM estimate for 2013 (consensus of $243MM) driven by new launches and firming base business performance.”

Sagent Pharmaceuticals closed on Friday at $15.70.

Latest Ratings for SGNT

DateFirmActionFromTo
Apr 2015Deutsche BankInitiates Coverage onBuy
Dec 2014JefferiesMaintainsHold
Oct 2014JefferiesMaintainsHold

View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SGNT)

Around the Web, We're Loving...